Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
recombinant cholera toxin subunit B
- Development stage
- Unknown
- Lead developer
- Valneva
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Administration
- Oral, Intranasal, Sublingual
01
Overview
Recombinant cholera toxin subunit B (rCTB) is a recombinant protein consisting of the non-toxic homopentameric B-subunit of cholera toxin. It binds with high affinity to GM1 ganglioside receptors on cell surfaces, facilitating mucosal and systemic immune responses without the toxicity associated with the catalytic A-subunit. rCTB is a key component of the oral cholera vaccine Dukoral (developed by SBL Vaccin, now Valneva) and has been investigated as a mucosal adjuvant, a diagnostic tool, and an immunomodulatory agent for inflammatory conditions such as Crohn's disease and asthma.
- Brand names
- Dukoral
- Other names
- CTBCTxBcholera toxin B subunitcholera toxin subunit BrCTBrecombinant cholera toxin B subunit
02
Targets
GM1 (GM1 ganglioside)
Beyond the preview
Go deeper on recombinant cholera toxin subunit B.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on recombinant cholera toxin subunit B.